11.98
-0.07 (-0.58%)
| Penutupan Terdahulu | 12.05 |
| Buka | 11.79 |
| Jumlah Dagangan | 881,220 |
| Purata Dagangan (3B) | 2,374,891 |
| Modal Pasaran | 849,387,456 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.46 |
| Harga / Buku (P/B) | 8.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Mar 2026 |
| EPS Cair (TTM) | -3.04 |
| Nisbah Semasa (MRQ) | 1.16 |
| Aliran Tunai Operasi (OCF TTM) | -142.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.50 M |
| Pulangan Atas Aset (ROA TTM) | -30.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Omeros Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.50 |
|
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.40% |
| % Dimiliki oleh Institusi | 47.30% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ingalls & Snyder Llc | 31 Dec 2025 | 3,448,699 |
| Stifel Financial Corp | 31 Dec 2025 | 1,809,766 |
| Nomura Holdings Inc | 31 Dec 2025 | 655,021 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (HC Wainwright & Co., 233.89%) | Beli |
| Median | 38.00 (217.20%) | |
| Rendah | 36.00 (D. Boral Capital, 200.50%) | Beli |
| Purata | 38.00 (217.20%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 13.06 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 27 Jan 2026 | 36.00 (200.50%) | Beli | 12.67 |
| 08 Jan 2026 | 36.00 (200.50%) | Beli | 13.45 | |
| HC Wainwright & Co. | 08 Jan 2026 | 40.00 (233.89%) | Beli | 13.45 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DEMOPULOS GREGORY A MD | - | 11.75 | -357,678 | -4,202,717 |
| Jumlah Keseluruhan Kuantiti Bersih | -357,678 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -4,202,717 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 11.75 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DEMOPULOS GREGORY A MD | Pegawai | 18 Feb 2026 | Dibuang (-) | 357,678 | 11.75 | 4,202,717 |
| DEMOPULOS GREGORY A MD | Pegawai | 18 Feb 2026 | Pelaksanaan pilihan | 400,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | Omeros Announces First Commercial Sales of YARTEMLEA® |
| 26 Dec 2025 | Pengumuman | Omeros Announces New Date for YARTEMLEA® Approval Conference Call |
| 24 Dec 2025 | Pengumuman | FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |